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MicroRNA Expression Profiles Associated with
Mutational Status and Survival in Malignant
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Stefano Caramuta1, Suzanne Egyha´zi2, Monica Rodolfo3, Daniela Witten4, Johan Hansson2,
Catharina Larsson1 and Weng-Onn Lui1
Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in early
melanoma diagnosis, the 5-year survival rate remains low in advanced disease. Therefore, novel biomarkers are
urgently needed to devise new means of detection and treatment. In this study, we aimed to improve our
understanding of microRNA (miRNA) deregulation in melanoma development and their impact on patient
survival. Global miRNA expression profiles of a set of melanoma lymph node metastases, melanoma cell lines,
and melanocyte cultures were determined using Agilent array. Deregulated miRNAs were evaluated in relation
with clinical characteristics, patient survival, and mutational status for BRAF and NRAS. Several miRNAs were
differentially expressed between melanocytes and melanomas as well as melanoma cell lines. In melanomas,
miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation. Furthermore, low
expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survival.
In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established
molecular backgrounds of BRAF and NRAS oncogenic mutations. The identification of an miRNA classifier for
poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical
practice.
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INTRODUCTION
Cutaneous malignant melanoma is a highly aggressive
disease accounting for the majority of skin tumor-related
deaths worldwide. The tumors originate from melanocytes,
and are associated with risk factors such as ultraviolet
radiation exposure, fair skin type, and predisposing gene
mutations. Despite improvements in early melanoma diag-
nosis, the 5-year survival rate for patients with advanced
disease is only 15% (Garbe and Eigentler, 2007; Villanueva
and Herlyn, 2008). Currently, the most powerful prognostic
factors for cutaneous melanoma at early stage are Breslow’s
tumor thickness, ulceration of the primary tumor, and
sentinel lymph node status.
Activating BRAF mutations, which affect the mitogen-
activated protein kinase (MAPK) pathway, are detected in
50–70% of melanomas (Davies et al., 2002). NRAS mutations
are present in 15–30% of melanoma tumors (Chin et al.,
1999), and cause constitutive activation of the MAPK
pathway independent of BRAF. NRAS and BRAF
mutations rarely co-exist, suggesting that they have biologi-
cally equivalent effects in melanoma development
(Omholt et al., 2003; Curtin et al., 2005). Inhibition of BRAF
or NRAS appears to be a promising route for development of
novel therapeutic tools in the treatment of metastatic
melanoma.
MicroRNAs (miRNAs) are short non-coding RNAs regula-
ting gene expression in many biological processes, including
proliferation, apoptosis, and differentiation (Ambros, 2001;
Bartel, 2004; He and Hannon, 2004; Kim, 2005). Expression
and functional studies indicate that altered miRNA expre-
ssion is critical for disease development. Global miRNA
expression studies in cutaneous melanoma have provided
evidence that miRNAs are deregulated during melanoma
progression (Gaur et al., 2007; Mueller et al., 2009). While
these studies have been limited to cell lines, virtually nothing
is known about the miRNA expression in clinical melanoma
materials.
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In this study, we carried out genome-wide miRNA
expression profiling in melanoma lymph node metastases
and melanoma cell lines in comparison with melanocytes.
Subgroups of deregulated miRNAs were found to be
associated with BRAF mutational status. In addition, we
identified a subset of miRNAs associated with significantly
shorter melanoma-specific survival.
RESULTS
The miRNA profiles of 16 clinical samples of melanoma
lymph node metastases (M-1 to 16), 21 melanoma cell lines
from 19 patients and three reference melanocyte cultures
(Table 1 and see online Supplementary Table S1) were
evaluated using microarray. After normalization and filtra-
tion, 167 miRNAs with X80% present calls across the
samples remained for further analysis.
miRNA expression patterns in melanomas, melanoma cell lines,
and melanocytes
We performed unsupervised hierarchical clustering of the
167 filtered miRNAs among the melanomas, melanoma cell
lines, and melanocytes. The analysis grouped the samples
into subgroups based on similar miRNA expression patterns
without previous knowledge of sample identity. Both
melanomas and melanoma cell lines were clearly grouped
into separate clusters from melanocytes (Figure 1). We also
noted several distinct subgroups among the melanomas and
melanoma cell lines, suggesting distinct clinical or biological
characteristics of these samples. By hierarchical clustering of
the same set of filtered miRNAs among all the samples, we
found that the cell lines were grouped separately from the
melanomas (see online Supplementary Figure S1). Although
the melanoma cell lines displayed substantial differences in
miRNA expression, some similarities were found between the
melanomas and melanoma cell lines.
Deregulated miRNAs in melanomas versus melanocytes
To identify the most significant differentially expressed
miRNAs between melanomas and normal melanocytes, we
performed SAM (Significance Analysis of Microarray) analy-
sis, which resulted in 32 differentially expressed miRNAs
with a q-value (a measure of the false discovery rate (FDR)) of
0% (see online Supplementary Table S2). Thirteen of the
selected miRNAs were overexpressed, and 19 were under-
expressed in melanomas (see online Supplementary Table
S2). Many of these differentially expressed miRNAs were
co-expressed, as illustrated by their close location between
each other in the hierarchical clustering (Figure 1).
To further determine the minimal number of miRNAs that
can distinguish melanomas from melanocytes, we applied the
Prediction Analysis of Microarray (PAM) method on the 167
filtered miRNAs, instead of the SAM-selected miRNAs, to
avoid an over-fitting bias induced after selection, as
previously described (Simon et al., 2003). The analysis
revealed that the expression signature of a minimal number
of 10 miRNAs could best distinguish the two groups, resulting
in a prediction accuracy of 100% as determined by 10-fold
cross validation (see online Supplementary Table S3). All
miRNAs in the PAM classifier were also detected by SAM,
including underexpression of miR-192, let-7i, miR-194, miR-
211, miR-602, miR-582, miR-454-3p, and miR-132, and
overexpression of miR-126 and miR-801.
Table 1. Summary of clinical, histopathological, and
genetic characteristics for the melanomas and
melanoma cell lines in the miRNA-array screening
Parameter Melanomas1 Cell lines
Number of samples 16 21
Number of patients 16 19
Sex
Male 14 8
Female 2 11
Age at diagnosis
Median (range) years 62 (17–82) 51 (22–84)
Histopathology
SSM 10 9
NM 2 4
Other/n.a. 4 6
Breslow
o1 mm 5 1
1–2 mm 2 4
2.1–4.0 mm 6 3
44 mm 2 6
n.a. 1 5
Survival
Short (survival range 1–12 months) 8 n.a.
Long (survival range 60–134 months) 8 n.a.
BRAF sequence of exon 15
Wild-type 8 5
Mutated 8 14
NRAS sequence of exon 2
Wild-type 12 16
Mutated 4 2
n.a. — 1
Abbreviations: SSM, superficial spreading melanoma; NM, nodular
melanoma; n.a., not available or not applicable.
Clinical and mutation data for melanoma tumors and cell lines were
reported in Edlundh-Rose et al. (2006), Johansson et al. (2009), and
Daniotti et al. (2004).
1Melanomas were obtained from regional lymph node metastasis of
patients with cutaneous melanoma.
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Figure 1. Unsupervised clustering analysis of miRNA expression. Heat maps illustrating unsupervised clustering of miRNA expression profiling in melanocytes
(NM) and melanomas (M) (left), as well as melanocytes and melanoma cell lines established from primary tumors (MCp), nodal metastasis (MCn), and cutaneous metastasis
(MCc) (right). Clustering was based on all 167 miRNAs remaining after filtration of species with more than 20% missing values across the samples. Median-centered log
ratios for each miRNA are represented. The yellow and blue colors indicate relatively high and low expressions, respectively. Missing values are indicated in gray.
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Association between miRNA profiles and clinical
characteristics of melanoma cases
Using SAM, we analyzed miRNA expression data in relation
to clinical characteristics of melanoma cases. We did not
observe any differentially expressed miRNAs to be signifi-
cantly associated with age at diagnosis, gender, or Breslow
tumor thickness of the primary tumors (data not shown).
miRNA profiles in relation to BRAF and NRAS mutations in
melanomas
Using SAM, we identified three miRNAs as candidates to
discriminate BRAF mutant from both BRAF and NRAS wild-
type (wt) melanomas, with an FDR of 0% (see online
Supplementary Table S2; Figure 2). Of these, miR-565 was
also identified by SAM analysis as a candidate to distinguish
BRAF mutant from BRAF wt cases (see online Supplementary
Table S2; Figure 2). Only miR-663 was found to be
significantly underexpressed in NRAS mutant compared with
BRAF/NRAS wt cases. However, no miRNAs appeared to be
deregulated in BRAF and NRAS mutated compared with
wt cases.
To verify the differential expression of miR-193a and miR-
338 between BRAF and NRAS wt and mutant samples
observed using microarray data, we evaluated the expression
of these two miRNAs in the same series of melanomas (M-1 to
16), as well as in an independent cohort of 16 additional
melanomas (M-17 to 32), using qRT-PCR. The strongest
association with BRAF mutation status was observed for
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Figure 2. miRNA expression profiles related to BRAF and NRAS mutational status. (a) Heat maps of array-based expression for the classifier of three
specific miRNAs obtained after SAM analysis. Comparisons for BRAF versus NRAS/BRAF wt samples (top) and BRAF-mutated melanomas versus NRAS mutated
and NRAS/BRAF wt melanomas (bottom) are illustrated. The yellow and blue colors indicate relatively high and low expressions, respectively. (b) Average
miR-193a expression in BRAF-mutated and BRAF/NRAS wt cases from two independent sets of cases measured by qRT-PCR. (c) Average expression level
of miR-193a and miR-338 assessed by qRT-PCR in relation to BRAF mutational status in two independent cohorts of patients. miRNA expression levels
between the groups were compared using t-tests.
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miR-193a, which showed significantly reduced levels in both
melanoma series (M-1 to -16, P¼0.009; M-17 to 32,
P¼0.032; t-test) (Figure 2). miR-338 alone was not sufficient
to distinguish BRAF mutant from BRAF/NRAS wt cases (M-1
to 16, P¼ 0.376; M-17 to 32, P¼ 0.169; t-test), but could in
combination with miR-193a accurately discriminate between
the two classes of melanomas (Po0.05 for both series;
Figure 2).
miRNA signature of survival in melanomas
We then determined whether the miRNA expression
signature could be used to predict melanoma-specific
survival. Among the 16 melanomas analyzed in the micro-
array experiments, eight patients had a short survival
measured from diagnosis of regional lymph node metastases
(range 1–12 months) and the remaining had a good prognosis
and long survival (range 60–134 months) after diagnosis.
For survival analysis, we considered patient M-4 as
‘‘censored’’ because of disease-unrelated death 7 months
after diagnosis.
Performing SAM analysis, we identified six candidate
miRNAs that could predict disease outcome with an FDR of
0% and a SAM survival score 41.5 (a modified score statistic
for a univariate Cox proportional hazards model). Melanomas
from patients with short survival showed underexpression of
miR-191, whereas miR-193b, miR-365, miR-338, let-7i, and
miR-193a were overexpressed (see online Supplementary
Table S4). This association was further assessed by Kaplan–-
Meier survival curves and log-rank analysis. Low expression
of miR-191 was associated with short survival (Po0.001, log-
rank test) as well as high expression of miR-193b (P¼0.026),
let-7i (P¼ 0.004), and miR-365 (P¼0.043). On the other
hand, miR-193a (P¼0.109) and miR-338 (P¼0.06) did not
reach statistical significance (see online Supplementary
Figure S2).
To verify microarray data, we measured the expression of
four miRNAs using qRT-PCR. Three of these showed a
significant correlation between microarray and qRT-PCR-
based expression values as assessed by Pearson correlation
analysis, that is, miR-193b (Cor ¼ 0.8625; Po0.0001), let-7i
(Cor ¼ 0.4822, P¼ 0.0252), and miR-365 (Cor ¼0.4353,
P¼0.041), whereas miR-191 (Cor ¼ 0.2896, P¼ 0.1612) did
not show significant correlation. However, Kaplan–Meier
survival curves and log-rank analysis showed a significant
association with survival for miR-191, in concordance with
array-based results, whereas let-7i and miR-365 are not
statistically significant.
To further validate this prognostic miRNA signature, we
performed qRT-PCR analyses for miR-191 and miR-193b in
an independent cohort of 16 melanomas (M-17 to 32; see
online Supplementary Table S1). Univariate Cox proportional
hazard models were fitted to evaluate the association of
miRNA expression with survival. We confirmed significant
associations for miR-191 (P¼0.0004) and miR-193b
(P¼0.0099). Patients with low expression of miR-191 and
high expression of miR-193b were found to have significantly
shorter survival (miR-191, P¼ 0.005; and miR-193b,
P¼0.004; log-rank test) (Figure 3).
Comparison of miRNA profiles in melanomas and melanoma
cell lines
In the microarray experiments, we found that the melano-
cytes, melanoma cell lines, and melanomas were clustered
into separate branches (see online Supplementary Figure S1).
We next identified miRNAs that are differentially expressed
between the melanocytes and all melanomas (including both
clinical samples and cell lines) using SAM. Nine miRNAs
could distinguish the melanomas and the cell lines from the
non-neoplastic counterpart (see online Supplementary Table
S5). Of these, seven (miR-192, miR-194, miR-132, miR-602,
miR-211, let-7i, and miR-509) were also significantly under-
expressed in melanomas compared with melanocytes.
We also compared the miRNA expression of melanomas
(that consisted of lymph node metastases) with the miRNA
expression of melanoma cell lines established from nodal
metastases (MCn). Thirty-nine miRNAs were found to be
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Figure 3. Associations between miRNA expression levels and survival.
Kaplan–Meier plots illustrating significant associations between high miR-
193b and low miR-191 expression and poor melanoma-specific survival in
the second set of melanoma cases (M-17 to 32). High or low expression levels
of the two miRNAs were determined by qRT-PCR analyses. Differences in
survival were calculated using log-rank test.
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differentially expressed between the two groups on the basis
of SAM analysis (see online Supplementary Table S5). By
comparing the list of miRNAs for melanomas versus
melanocytes (see online Supplementary Table S2) and MCn
versus melanocytes (see online Supplementary Table S5), we
found six miRNAs that were commonly downregulated in
both melanomas and melanoma cell lines of nodal metas-
tases (Table 2). Interestingly, miR-211 and miR-509 were the
most significantly downregulated miRNAs in nodal meta-
stases (Po0.0001).
DISCUSSION
Here, we report frequent dysregulation of miRNA expression
in lymph node metastases of malignant melanomas with
implications for patient survival and associations to muta-
tional status. Our findings show differential miRNA expres-
sion pattern in melanomas compared with melanocytes, and
thus extend previous observations of miRNA expression in
melanoma cell lines (Mueller et al., 2009).
We found substantial differences in miRNA expression
patterns between the cell lines and the clinical samples,
although both entities were clearly distinct from the
melanocytes used as non-neoplastic counterparts. Possible
explanations include modifications of miRNA transcription as
a direct effect of culturing conditions such as exposure to
growth factors, as well as those resulting from acquired
genetic changes following adaptation to in vitro culturing.
Alternatively, the differences might be due to the hetero-
geneity of cell types within the tumor samples. Nevertheless,
a common miRNA expression signature was observed
between the cell lines and clinical samples, indicating that
relevant gene regulatory networks are conserved in cell lines
after successive passages in culture.
Although we found significant correlation between micro-
array and qRT-PCR for most of the miRNAs, some discre-
pancies were observed. One possible explanation might be
due to differences in detection sensitivity and probe designs
for microarray (e.g., the probe length for miR-191 is only
16-nucleotides (nt), whereas the mature miRNA is 23-nt
long). Besides, the different normalization processes might
account for discrepancies observed between the two plat-
forms: microarray uses a global normalization for comparison
across the samples, whereas qRT-PCR data are normalized
using one reference gene that is assumed to be constant in all
samples analyzed.
Altered miRNA expression in melanoma
SAM and PAM comparisons of melanomas and melanocytes
identified 10 significant differentially expressed miRNAs.
Seven of these were also differentially expressed in the
melanoma cell lines compared with melanocytes. Two of the
most significant miRNAs, miR-192 and miR-194, which are
located close to each other, were found to have low
expression in melanoma. This is consistent with recent
studies (Gaur et al., 2007; Mueller et al., 2009), which
showed that miR-192 and/or miR-194 were also down-
regulated in melanoma cell lines, further supporting their
relevance in melanoma. The co-expression of the clustered
miR-192 and miR-194 suggests a possible co-regulation by
common transcriptional factor(s) and common function(s). In
line with this hypothesis, Hino et al. (2008) showed that the
miR-192 to 194 cluster is encoded by a single primary
miRNA transcript and induced by hepatocyte nuclear factor-
1a, HNF-1a. HNF-1a is an important regulator of various
genes specific to the intestine, and it is also expressed in other
tissue types, including human skin melanocytes (Schallreuter
et al., 2003). Furthermore, miR-192 was found to be
regulated by p53, and has an important role in cell cycle
control and proliferation (Braun et al., 2008; Georges et al.,
2008; Song et al., 2008). The role of the miR-192 to 194
cluster in melanoma cells and its regulation by HNF-1a/p53
are certainly worthy of further investigation.
Another miRNA, miR-211, was significantly less abundant
in the melanomas and melanoma cell lines compared with
the normal counterparts. This miRNA was also found to be
downregulated in a highly invasive melanoma cell line
compared with its isogenic cell line with low invasive
potential (Mueller et al., 2009). Interestingly, miR-211 is
transcribed from the TRPM1 gene. Loss of TRPM1 expression
strongly predicts melanoma progression and poor clinical
outcome in human cutaneous melanoma (Duncan et al.,
2001; Hammock et al., 2006); thus, it is an important
prognostic marker. Although the role of TRPM1 in melanoma
progression is unknown, a recent study suggested that TRPM1
function is critical for melanocyte pigmentation (Oancea
et al., 2009). Given that miR-211 is likely co-transcribed with
its host gene TRPM1, further investigation of the clinical and
biological significance of miR-211 in melanoma develop-
ment is warranted.
A recent study by Segura et al. (2009) showed over-
expression of miR-182 in a subset of melanoma cell lines and
some metastatic melanoma samples. In our microarray data,
the expression of miR-182 was undetectable in all melano-
cytes and half of the melanoma tumors. The remaining
melanoma tumors show low miR-182 expression. Therefore,
we could not evaluate its significance by statistical analysis.
Table 2. Array results of miRNAs commonly
underexpressed in melanomas (M) and cell lines
(MCn) compared to melanocytes
Normalized expression value (mean ± SD)
miRNA NM M + MCn P-value
miR-211 0.0197±0.0143 0.0106±0.1165 o0.0001
miR-509 0.1499±0.0229 0.0042±0.0998 o0.0001
miR-132 0.1786±0.0488 0.0100±0.0776 0.0094
miR-194 0.1996±0.0798 0.0178±0.0763 0.0326
miR-192 0.2681±0.0989 0.0021±0.0598 0.0379
miR-602 0.2063±0.1001 0.0207±0.0913 0.0446
Abbreviations: NM, melanocytes; M, melanomas; MCn, melanoma cell
lines from nodal metastases.
P-values were determined by unpaired t-test and values of Po0.05 were
considered significant.
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The authors also showed that ectopic expression of miR-182
promotes lung metastasis in a mouse model, suggesting a
possible role for miR-182 in distant metastasis (e.g., in lung),
which may not have a significant role in regional lymph node
metastasis.
miRNA signature of poor survival in melanoma
We showed that high expression of miR-193b and low
expression of miR-191 in melanomas were significantly
associated with poor survival. miR-193b is also highly
expressed in head and neck squamous cell carcinoma
(Avissar et al., 2009), and has been shown to be associated
with high risk of metastatic disease in uveal melanoma
(Worley et al., 2008). Besides its expression association,
virtually nothing is known about the function of miR-193b.
Computational methods (miRanda, TargetScan 5.1, and
PicTar_vertebrate) predict hundreds of miR-193b target
mRNAs (Supplementary Table S6). Among the predicted
targets, PTEN, an important tumor suppressor that negatively
regulates the Akt-signaling pathway, has been implicated
in melanoma tumorigenesis and progression. Importantly,
altered PTEN expression is common in primary melanoma
and associated with metastatic disease (Stahl et al., 2003;
Mikhail et al., 2005; Dankort et al., 2009). However, the
functional roles of miR-193b and its target(s) remain to be
further investigated.
We found reduced levels of miR-191 to be associated with
short survival in melanoma, which is in contrast to a previous
report showing that high expression of miR-191 was
associated with poor survival in acute myeloid leukemia
patients (Garzon et al., 2008). Although high miR-191
expression is found in several cancer types, including the
colon, lung, pancreas, prostate, and stomach (Volinia et al.,
2006; Yanaihara et al., 2006), it remains possible that the
activity of specific miRNA varies in different tissues or cell
types. For example, inhibition of miR-191 caused increased
cell proliferation in HeLa cervical cancer cells, but decreased
proliferation in A549 lung cancer cells (Cheng et al., 2005).
Furthermore, Mueller et al. (2009) found high expression of
miR-191 in a melanoma cell line stably transfected with
antisense targeting of SNAIL compared with its parental cell
line. Snail, a member of the Snail family of transcription
factors, has been shown to be involved in epithelial–me-
senchymal transition (a hallmark of invasiveness) (Batlle
et al., 2000; Cano et al., 2000). The Snail knockdown mutant
lost its invasive propensity because of loss of repression of E-
cadherin expression by Snail (Kuphal et al., 2005). The high
expression of miR-191 in the non-invasive melanoma cell
line (i.e., Snail knockdown) corresponds well with a good
prognosis and long survival in melanoma patients. Computa-
tional analysis revealed a number of predicted targets for
miR-191 (Supplementary Table S6), which have been shown
to be involved in melanoma progression, e.g., FZD5
(Bachmann et al., 2005) and BDNF (Innominato et al., 2001).
miRNA expression associated with BRAF/NRAS mutation
We found two significant associations when comparing
NRAS/BRAF mutant tumors with those that were wild type
for both genes: (i) low expression of miR-193a, miR-338, and
miR-565 was associated with cases carrying a BRAF missense
mutation at the commonly involved residue V600; and (ii)
reduced expression of miR-663 was associated with NRAS-
mutated cases. In contrast, there were no significant
differentially expressed miRNAs between BRAF versus NRAS
mutated melanomas. Furthermore, we did not find any
miRNAs that were commonly deregulated in BRAF/NRAS-
mutated melanomas compared with BRAF/NRAS wild-type
cases. This observation suggests that BRAF and NRAS might
regulate distinct signaling pathways, in addition to the
common MAPK-signaling pathway. The finding is consistent
with global mRNA expression array studies (Daniotti et al.,
2004; Pavey et al., 2004; Giordano et al., 2005). Together,
the data would be in agreement with a model where BRAF
and NRAS contribute to melanoma development through
partly overlapping and partly distinct pathways (Dumaz et al.,
2006; Eskandarpour et al., 2009; Huang and Marais, 2009;
Jaiswal et al., 2009; Old et al., 2009).
miR-193a was observed as the strongest discriminator
between BRAF-mutated and wild-type melanomas. Interest-
ingly, this miRNA was also reported as downregulated in
BRAFV600E-mutated thyroid cancer cell lines compared with
normal thyroid tissue (Cahill et al., 2007). miR-193a is the
only common deregulated miRNA associated with
BRAF mutation in both papillary thyroid cancer (Cahill
et al., 2007) and our melanoma series, suggesting that miR-
193a may have an important and common role in BRAF-
associated events in MAPK and/or other signaling pathways.
It is noted that some of the predicted targets by computational
analysis are associated with MAPK pathway (Supplementary
Table S7). Elucidation of the targets of miR-193a may
lead to a further understanding of the pathological role of
BRAF mutation, and development of novel therapeutic
targets.
Prospect for clinical utility of miRNAs as biomarkers
Our study shows frequent dysregulation of miRNAs in
melanomas with identification of a classifier for poor
survival. On confirmation of the prognostic value in
independent melanoma series, miRNA detection could be
developed into complementary diagnostic tools in clinical
pathology. In this context, detection of miRNA expression
would have several advantages compared with e.g., detec-
tion of coding gene transcripts. Mature miRNA species are
comparatively stable and preserved in paraffin-embedded
samples commonly used in clinical routine. In addition,
analyses of miRNA species in individual cells may be
applied on paraffin-embedded melanoma tissues that are
frequently heterogeneous with related problems of tumor cell
representation.
MATERIALS AND METHODS
Melanoma cell lines and melanocytes
Generation, characterization, and culturing conditions for the 21
melanoma cell lines included in the study have been previously
reported in detail (Daniotti et al., 2004). The cell lines were derived
from primary melanomas (MCp-1 to 4), lymph node metastases
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(MCn-1 to 8), or cutaneous metastases (MCc-1 to 9) of 19 patients
with cutaneous malignant melanoma. Three lines (MCp-2, MCn-8,
and MCc-7) originated from the same patient. Melanoma cell lines
had been propagated for 5–51 passages (median ¼ 18). Information
of originating tumor phenotypes and genetic status for BRAF and
NRAS, as previously determined (Daniotti et al., 2004), is given in
Supplementary Table S1. Human melanocyte cultures (NM-1 to 3)
(PromoCell, Heidelberg, Germany) from three different individuals
were included as non-neoplastic provenience. Ethics approval was
obtained for the use of all samples.
Melanomas
A total of 32 samples from fresh frozen regional lymph node
metastases of patients with cutaneous melanoma were studied (M-1
to 32; Supplementary Table S1). The study was approved by the
ethics committee of Karolinska University Hospital and conducted in
adherence to the Declaration of Helsinki protocols. All tumors were
obtained with informed consent of the patients and were all present
and collected at the time of initial diagnosis. All patients had
regional lymph node metastases (AJCC stage III disease) and
represented cases with poor or good prognosis in terms of
melanoma-specific survival, and all tumors have been characterized
for genetic status of BRAF exon 15 and NRAS exon 2 as previously
reported for the majority of cases (Edlundh-Rose et al., 2006;
Johansson et al., 2009).
RNA extraction
Total RNA was extracted using mirVana miRNA Isolation Kit
(Applied Biosystems/Ambion, Austin, TX), and RNA concentrations
were determined with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
miRNA microarray experimentation and analyses
miRNA expression profiling was performed using Human Agilent’s
miRNA Microarray system (Agilent, Santa Clara, CA) with probe sets
for 470 human miRNAs (miRBase release 9.1). In brief, 120 ng of
total RNA were fluorescence-labeled with Cyanine 3-pCp, and
hybridized onto the arrays for 18–20 h at 55 1C. Slides were scanned
in an Agilent microarray scanner G2565BA and the images obtained
were processed with Feature Extraction Software 9.5.3.1 (Agilent).
Intensity values were processed using Cluster 3.0 software whereby
data were normalized, log transformed, and median centered. Only
normalized miRNAs with less than 20% missing values across the
samples were included in the further analysis. The microarray data
have been deposited at NCBI Gene Expression Omnibus (GEO
accession number, GSE19387).
Hierarchical clustering (average linkage with uncentered correla-
tion) of the samples and miRNAs was performed using Cluster 3.0
software and visualized with Treeview v1.60. Significance Analysis of
Microarrays (SAM) (http://www-stat.stanford.edu/Btibs/SAM/) was
applied to determine the association of each miRNA with sample
groups, melanoma-specific survival, as well as clinical and genetic
parameters including age at diagnosis, gender, Breslow tumor
thickness, and BRAF/NRAS mutational status. A total of 1000
permutations were performed to estimate false discovery rates for
the resulting score statistics. Prediction Analysis of Microarrays (PAM)
(http://www-stat.stanford.edu/Btibs/PAM/) was used to construct a
classifier to predict sample groups based on miRNA expression.
Quantitative Reverse Transcription-PCR (qRT-PCR)
Expression of selected mature miRNAs was assessed by
qRT-PCR. cDNA was prepared from total RNA using Taqman
MicroRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). Predesigned TaqMan MicroRNA Assays for miR-
191 (ID 002299), miR-193b (ID 002367), let-7i (ID 002221), miR-
338-3p (ID 002252), miR-365 (ID 001020), and miR-193a-3p (ID
002250) were purchased from Applied Biosystems and
qRT-PCR was performed using an Applied Biosystems 7500 Fast
Real-Time PCR System. All reactions were run in triplicate
and normalized to the expression of RNU6B (ID 001093).
Relative expressions were determined with the DCT method and
reported as 2DCT.
Statistical analysis of individual miRNAs
Microarray and qRT-PCR results were compared using Pearson’s
correlation: the microarray and qRT-PCR measurements were
computed, and P-values were estimated by permuting the samples.
Unpaired t-test was used to compare miRNA expression in different
groups of samples. SAM survival analysis was used to determine
association of miRNAs with survival. P-values were obtained for the
Cox score statistics using the w2 distribution. At retrospective follow-
up, survival information was collected for the 32 cases of melanoma
tumors (see online Supplementary Table S1). Survival was defined as
the time from the first diagnosis of regional lymph node metastasis
until the date of death or last follow-up; melanoma-specific survival
was the outcome of interest, and therefore cases that died of a cause
other than disease were treated as censored. Fourteen cases died of
the disease within 1–13 months (poor prognosis), two cases died of
unknown or melanoma-unrelated cause of death, and 16 cases
survived for 60 months or more (good prognosis). Tumor samples
were classified into different groups with high or low expression of
each miRNA, according to the median level of expression.
Kaplan–Meier plots were used to graphically display the association
of miRNAs with the outcome. Survival curves for each group were
compared using the log-rank test. Univariate Cox proportional
hazards models were used to evaluate the association of miRNA
expression with survival. All P-values obtained in this study
were 2-tailed. P-values o0.05 were considered significant.
Statistical calculations were performed using Statistica 8.0
(StatSoft, Tulsa).
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